Agomab Therapeutics director David R. Epstein reports $27,850 common share acquisition
AGMB•Agomab Therapeutics director David R. Epstein purchased 5,000 common shares at $5.57 each, increasing his direct holdings to 59,980 shares.
AGMB•Agomab Therapeutics director David R. Epstein purchased 5,000 common shares at $5.57 each, increasing his direct holdings to 59,980 shares.
David R. Epstein purchased 5,000 Agomab Therapeutics common shares at $5.57 per share, a total of $27,850. His direct holdings increased to 59,980 common shares.